Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy

Qingle Ma,Qin Fan,Xiao Han,Ziliang Dong,Jialu Xu,Jinyu Bai,Weiwei Tao,Dongdong Sun,Chao Wang
DOI: https://doi.org/10.1016/j.jconrel.2020.11.064
IF: 11.467
2021-01-01
Journal of Controlled Release
Abstract:<p>Atherosclerosis is a kind of chronic inflammatory diseases characterized by dysfunction of local immune responses. Here we engineer platelet-derived extracellular vesicles (PEVs) to load MCC950, an NLRP3-inflammasome inhibitor, for atherosclerosis-targeted therapy. PEVs which are readily collected from the activated platelets selectively bind multiple cell types associated with the formation of atherosclerotic plaque <em>in vivo</em>. Intravenous administration of MCC950-PEVs could significantly reduce the formation of atherosclerotic plaques, lower the local inflammation and inhibit proliferation of macrophages and T cells at the plaque site compared with free drug administration in ApoE-KO mice. Our strategy suggests the promise of PEVs for targeted drug delivery for treatment of atherosclerosis.</p>
pharmacology & pharmacy,chemistry, multidisciplinary
What problem does this paper attempt to address?